Tech
To keep drug prices high, pharma has been piling up the patents
Publication: Ars Technica - All content
Author: Beth Mole
Source published: 28/09/2026, 19:53:37 UTC
Briefing created: 28/09/2026, 22:17:29 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/09/2026, 22:13:24 UTC.
Briefings
A 2026 JAMA study reveals that US drug patents have tripled since 1990, with nonprimary patents accounting for most growth. This expansion creates 'patent thickets' that delay generic entry and sustain high drug prices. The article notes that while healthcare costs are a pre-existing condition for Americans, drug price exploitation remains a significant pain point.
Key points
- A 2026 study in JAMA found the number of patents on small-molecule drugs has more than tripled since 1990, rising from an average of 2.1 to 6.9 per approved drug.
- The majority of this growth occurred in 'nonprimary' patents, which protect minor tweaks to nonactive ingredients, usage instructions, or delivery device designs rather than the active drug ingredient.
Context and limitations
The evidence is from a 2026 JAMA study published Monday, and the article does not provide specific data on the total number of drugs affected or the exact financial impact on individual patients.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/09/2026, 22:17:29 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifryfyhtggtsw5gx4ldwjqaefqyjgepgdsjnhxwbslifhzxbiyp3i